<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39365687</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8336</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>09</Day></PubDate></JournalIssue><Title>Expert review of anti-infective therapy</Title><ISOAbbreviation>Expert Rev Anti Infect Ther</ISOAbbreviation></Journal><ArticleTitle>The efficacy and safety of hydroxychloroquine at different doses and courses for COVID-19 prevention: a systematic review and network meta-analysis.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>12</EndPage><MedlinePgn>1-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14787210.2024.2413419</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The optimal strategy for using hydroxychloroquine to prevent coronavirus disease 2019 (COVID-19) in patients, either before or after exposure, remains unclear. We evaluated the safety and efficacy of different doses and treatment durations of hydroxychloroquine for COVID-19 prevention.</AbstractText><AbstractText Label="METHOD" NlmCategory="UNASSIGNED">Databases including PubMed, Web of Science, Cochrane Library, EMBASE, Medline, and ClinicalTrials.gov were systematically searched for randomized controlled trials (RCTs) comparing different doses of hydroxychloroquine for COVID-19 prevention, from their inception to February 2024.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 20 RCTs involving 12,372 patients were included. Meta-analysis results showed no significant difference between the hydroxychloroquine and control groups in reducing the incidence of syndrome coronavirus type 2 (SARS-CoV-2) positivity (OR = 0.83, 95% CI = 0.67, 1.03). However, the subgroup receiving a daily dose of 200-400 mg (OR = 0.62, 95% CI = 0.51, 0.75) and a treatment duration of 5-8 weeks (OR = 0.52, 95% CI = 0.31, 0.88) showed statistically significant reductions in SARS-CoV-2 positivity. According to the surface under the cumulative ranking curve (SUCRA), the most effective intervention was a 200-400 mg dose for 5-8 weeks.  .</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">A hydroxychloroquine dose of 200-400 mg for a duration of 5-8 weeks may moderately reduce the risk of COVID-19 with a relatively low risk of adverse events.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, National Regional Medical Center, Binhai Campus of The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qiyuan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, National Regional Medical Center, Binhai Campus of The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Yinjun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, National Regional Medical Center, Binhai Campus of The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Haibo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Pinfang</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, National Regional Medical Center, Binhai Campus of The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhan</LastName><ForeName>Zhikun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, National Regional Medical Center, Binhai Campus of The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Anti Infect Ther</MedlineTA><NlmUniqueID>101181284</NlmUniqueID><ISSNLinking>1478-7210</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">network meta-analysis</Keyword><Keyword MajorTopicYN="N">prevention</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39365687</ArticleId><ArticleId IdType="doi">10.1080/14787210.2024.2413419</ArticleId></ArticleIdList></PubmedData></PubmedArticle>